Clinical trials: Gastric (Stomach) Cancer
Cancer
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
RATIONALE: PV701 may be able to kill tumor cells while leaving normal cells undamaged. PURPOSE: Phase I trial to study the effectiveness of PV701 in treating patients who have advanced or recurrent ovarian epithelial, fallopian…
- Trial name
- NCT00055705
- Testing
- PV701
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
The purpose of the study is to test the safety and dosing of [177Lu]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme
- Trial name
- NCT05977322
- Testing
- 68Ga-FF58, 177Lu-FF58
- Where
- 5 sites in Israel, Netherlands and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Survival
Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer
The investigators intend to conduct a randomized controlled study to find if combining HIPEC (hyperthermic intraperitoneal perfusion chemotherapy) with post-neoadjuvant chemotherapy D2 resection could improve survival for…
- Trial name
- HIPEC (NCT02960061)
- Testing
- Neoadjuvant chemotherapy, D2 radical resection, Hyperthermic intraperitoneal perfusion chemotherapy
- Where
- China
- Volunteers
- 640 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Gastrointestinal Tumor
Phase I Trial of Combination of FOLFIRI and SOM 230
This is a single-arm, open-label, phase I study of combination therapy with SOM 230 and FOLFIRI. We will utilize a sequential dose-escalation design to define the maximum tolerated dose (MTD) of SOM 230 when combined with…
- Trial name
- NCT01434069
- Testing
- SOM230C LAR, FOLFIRI Infusion
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
This is a Phase 1, open-label, two-part, safety, PK, and activity study designed to characterize the DDI potential of tazemetostat. Tazemetostat will be taken orally BID continuously in 28-day cycles in both study parts.
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma, Advanced Solid Tumor
- Trial name
- NCT03028103
- Testing
- Tazemetostat, Fluconazole, Omeprazole
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Epizyme, Inc.
Esophageal Cancer, Esophageal Dysplasia
Comparison of O-type Hybrid Knife and IT Knife in ESD
By combining injection and dissection capability together, O-type Hybrid knife could possibly shorten the endoscopic submucosal dissection procedure for upper gastrointestinal neoplasms.
- Conditions
- Esophageal Cancer, Esophageal Dysplasia, Stomach Cancer, Stomach Dysplasia
- Trial name
- NCT01760070
- Testing
- Hybrid knife, IT knife
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Gastric Cancer Stage III
A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma
The goal of this clinical trial is to learn if FLOT chemotherapy combined with serplulimab can improve the pathological complete response (pCR) rate in patients with stage III gastric cancer.
- Trial name
- NCT07257575
- Testing
- FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)+Serplulimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Guangdong Provincial People's Hospital
Gastric Cancer, Colorectal Cancer
Status of Management of Surgery in Beijing During COVID-19
This is a multi-centered, retrospective, observational study aimed at observing the current status of the management of gastrointestinal surgery during the COVID-19 pandemic, particularly the changes on surgery protocols and…
- Conditions
- Gastric Cancer, Colorectal Cancer, Gastrointestinal Disease
- Trial name
- NCT04401124
- Testing
- no intervention
- Volunteers
- 500 people
- Sponsor
- Beijing Friendship Hospital
Gastro-esophageal Reflux
Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy
The purpose of this research study is to measure acid reflux into the throat both before and after medical treatment in people who have had radiation therapy to their head and neck for the treatment of cancer.
- Trial name
- NCT00222079
- Testing
- Esomeprazole (Nexium)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Douglas Trask
Gastrointestinal Cancer, Gastric Cancer
NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers
The NOMAD-GI study is a single-center, bidirectional cohort study designed to evaluate the safety and efficacy of molecular biomarker-guided non-operative management (NOM) and organ preservation strategies after precision therapy…
- Conditions
- Gastrointestinal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer
- Trial name
- NOMAD-GI (NCT07775859)
- Volunteers
- 200 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Cancer, Gastric Cancer
Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma
The purpose of this study is to collect anti-tumor activity of vinorelbine when given to patients with esophageal or gastric tumors. We will also collect information on the toxicities of vinorelbine in these patients.
- Conditions
- Esophageal Cancer, Gastric Cancer, Stomach Cancer
- Trial name
- NCT00215462
- Testing
- Vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Gastric Subepithelial Tumor
Endoscopic Full Thickness Resection With Laparoscopic Assistance
The purpose of this study is to evaluate the feasibility of endoscopic full-thickness resection with laparoscopic assistance.
- Trial name
- EFTR-LA (NCT02042079)
- Testing
- EFTR with LA
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- National Cancer Center, Korea
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression
To evaluate the efficacy and safety of anlotinib combined with TQB2450 and the SOX regimen as first-line treatment for advanced gastric cancer with low PD-L1 expression
- Trial name
- NCT06939452
- Testing
- anlotinib +TQB2450 + Oxaliplatin+S-1
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Yongxu Jia
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic…
- Trial name
- NCT07221149
- Testing
- Pumitamig, Folfox, Capox
- Where
- 161 sites in United States, Argentina and 18 more
- Volunteers
- 690 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer
A multicenter, randomized, open-label, phase III trial of S-1 plus cisplatin (3 weekly) versus S-1 plus oxaliplatin chemotherapy for the first-line treatment of advanced gastric cancer
- Trial name
- SOPP (NCT01671449)
- Testing
- S-1, Cisplatin, Oxaliplatin
- Where
- 9 sites in South Korea
- Volunteers
- 338 people
- Sponsor
- Min-Hee Ryu
Metastatic Colorectal Cancer
Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors
This study evaluates the safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients. Oral irinotecan will be administered as monotherapy in a dose escalation trial to establish the Maximal…
- Trial name
- NCT03295084
- Testing
- Irinotecan, Capecitabine
- Where
- Denmark
- Volunteers
- 39 people
- Sponsor
- Dorte Nielsen
Malignant Neoplasm of Stomach Stage II
Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric cancer which paclitaxel-resistant.
- Trial name
- NCT02697838
- Testing
- Apatinib, Paclitaxel-based chemotherapeutic regimens
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Advanced Gastric Cancer
Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
The purpose of this study is to determine whether Sunitinib and Docetaxel is effective in the treatment of advanced gastric cancer patients who had prior chemotherapy with fluoropyrimidine and platinum.
- Trial name
- NCT01238055
- Testing
- Docetaxel + Sunitinib, Docetaxel only
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- Samsung Medical Center
Gastric Cancer
Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer
The prognosis of metastatic gastric cancer is poor. Chemotherapy occasionally converts an initially unresectable gastric cancer to a resectable cancer.
- Trial name
- NCT02529878
- Testing
- S1/Paclitaxel chemotherapy plus Apatinib
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.